Inductive Bio, a pioneering technology company focused on democratizing artificial intelligence (AI) models for small molecule drug discovery, has secured $25 million in Series A funding. The round was led by Obvious Ventures, with notable participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective. The financing also attracted several angel investors, including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.
Inductive Bio’s innovative approach to AI is set to accelerate the drug discovery process, aiming to unlock new treatments and improve outcomes in healthcare. The company’s AI-driven platform is designed to make drug discovery more accessible and efficient, enabling breakthroughs in small molecule development.
The $25 million in funding will be used to further advance Inductive Bio’s AI-driven drug discovery platform, helping the company scale its operations and push the boundaries of innovation in the biotech space. With support from some of the leading venture firms and influential investors, Inductive Bio is well-positioned to drive significant change in the pharmaceutical industry, leveraging AI to solve complex challenges in drug discovery.
This new funding round highlights the growing interest in AI-driven technologies in healthcare, reflecting the increasing recognition of AI’s potential to transform the drug discovery landscape.
